Ronald Kapusta Biography and Net Worth



Johnson & Johnson said its controller and chief accounting officer, Ronald Kapusta, is retiring as of Dec. 27.

Robert Decker Jr. will replace Kapusta in the roles, the healthcare giant said in an Oct. 7 filing.

Decker joined the New Brunswick, N.J.-based company in 1993 and was appointed assistant corporate controller in August 2017.

What is Ronald A. Kapusta's net worth?

The estimated net worth of Ronald A. Kapusta is at least $1.96 million as of December 13th, 2018. Mr. Kapusta owns 13,641 shares of Johnson & Johnson stock worth more than $1,957,211 as of December 30th. This net worth evaluation does not reflect any other investments that Mr. Kapusta may own. Learn More about Ronald A. Kapusta's net worth.

How do I contact Ronald A. Kapusta?

The corporate mailing address for Mr. Kapusta and other Johnson & Johnson executives is ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ, 08933. Johnson & Johnson can also be reached via phone at (732) 524-0400 and via email at [email protected]. Learn More on Ronald A. Kapusta's contact information.

Has Ronald A. Kapusta been buying or selling shares of Johnson & Johnson?

Ronald A. Kapusta has not been actively trading shares of Johnson & Johnson during the last ninety days. Most recently, Ronald A. Kapusta sold 3,643 shares of the business's stock in a transaction on Thursday, December 13th. The shares were sold at an average price of $147.31, for a transaction totalling $536,650.33. Following the completion of the sale, the chief accounting officer now directly owns 13,641 shares of the company's stock, valued at $2,009,455.71. Learn More on Ronald A. Kapusta's trading history.

Who are Johnson & Johnson's active insiders?

Johnson & Johnson's insider roster includes Dominic Caruso (VP), Robert Decker (CAO), Joaquin Duato (CEO & Chairman), Peter Fasolo (VP), Alex Gorsky (CEO), William Hait (Insider), Ronald Kapusta (CAO), Ashley McEvoy (EVP), Thibaut Mongon (VP), William Perez (Director), Michael Sneed (COO), Paulus Stoffels (VP), James Swanson (EVP), Jennifer Taubert (EVP), Mark Weinberger (Director), Kathryn Wengel (EVP), Joseph Wolk (CFO), and Joseph Wolk (Exec. VP & CFO ). Learn More on Johnson & Johnson's active insiders.

Are insiders buying or selling shares of Johnson & Johnson?

During the last year, Johnson & Johnson insiders bought shares 1 times. They purchased a total of 1,000 shares worth more than $147,220.00. During the last year, insiders at the sold shares 3 times. They sold a total of 68,757 shares worth more than $10,308,224.54. The most recent insider tranaction occured on December, 12th when Director Mark A Weinberger bought 1,000 shares worth more than $147,220.00. Insiders at Johnson & Johnson own 0.2% of the company. Learn More about insider trades at Johnson & Johnson.

Information on this page was last updated on 12/12/2024.

Ronald A. Kapusta Insider Trading History at Johnson & Johnson

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/13/2018Sell3,643$147.31$536,650.3313,641View SEC Filing Icon  
11/8/2018Sell8,441$145.15$1,225,211.1517,284View SEC Filing Icon  
9/7/2018Sell7,899$137.18$1,083,584.8225,725View SEC Filing Icon  
7/22/2016Sell2,935$125.01$366,904.3528,660View SEC Filing Icon  
6/7/2016Sell3,000$115.79$347,370.0028,725View SEC Filing Icon  
5/10/2016Sell3,957$114.77$454,144.8929,682View SEC Filing Icon  
10/23/2015Sell6,239$99.68$621,903.5220,803View SEC Filing Icon  
See Full Table

Ronald A. Kapusta Buying and Selling Activity at Johnson & Johnson

This chart shows Ronald A Kapusta's buying and selling at Johnson & Johnson by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Johnson & Johnson Company Overview

Johnson & Johnson logo
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Read More

Today's Range

Now: $143.48
Low: $142.95
High: $144.88

50 Day Range

MA: $153.32
Low: $143.58
High: $165.86

2 Week Range

Now: $143.48
Low: $142.75
High: $168.85

Volume

1,443,633 shs

Average Volume

7,154,909 shs

Market Capitalization

$345.45 billion

P/E Ratio

20.76

Dividend Yield

3.38%

Beta

0.51